CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia – Yahoo Finance

TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation
Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-tolerated and manageable safety profile in Chinese adult patients with R/R AML who have a susceptible IDH1 mutation
TIBSOVO® became CStone's fourth innovative drug approved within 12 months after two first-in-class precision therapies GAVRETO® and AYVAKIT®, and the immuno-oncology therapy CEJEMLY®
SUZHOU, China, Feb. 9, 2022 /PRNewswire/ — CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the new drug application (NDA) of TIBSOVO® (ivosidenib tablets) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation, providing a new precision therapy for this patient population.
Acute myeloid leukemia (AML) is the most common type of leukemia in adults. The disease progresses rapidly, and the vast majority of patients are the elderly. In the US, there are about 20,000 new cases of AML each year, and the 5-year survival rate is about 29%. With the aging of the population, the incidence of AML in China has been rising, and particularly the elderly and relapsed/refractory patients have a poorer prognosis. In China, there are about 75.3 thousand new cases of Leukemia each year and approximately 59% are AML patients, among whom about 6-10% have IDH1 mutations.
Dr. Frank Jiang, Chairman and CEO of CStone, said, "This marks another milestone for CStone Pharmaceuticals. TIBSOVO® is our fourth innovative drug successfully approved, and it only took 6 months from NDA acceptance to NDA approval, demonstrating once again the 'CStone Speed'. Previously, CStone has successfully obtained regulatory approvals for the launch of two first-in-class precision medicines and a potential best-in-class immuno-oncology therapy. We will advance our broad and diversified pipeline of innovative products and aim to provide more high-quality innovative drugs for patients around the world."
Professor Wang Jianxiang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, the Principal Investigator of registrational bridging study CS3010-101 in China, said, "For a long time, there have been limited treatment options for AML patients with IDH1 mutations, and patients had a low 5-year survival rate and poor quality of life. We are excited that TIBSOVO®, as the first IDH1 inhibitor approved in China, demonstrated superior efficacy and safety in AML patients with IDH1 mutations. I believe that the approval of TIBSOVO® will offer an innovative precision therapy to more AML patients, helping improve their quality of life and prolong their lives."
Dr. Jason Yang, Chief Medical Officer of CStone, said, "We are thrilled that TIBSOVO® has been approved in Mainland China for the treatment of patients with R/R AML. As the first and only IDH1 inhibitor approved in China, TIBSOVO® demonstrated proven efficacy and well-tolerated safety in Chinese patients with R/R AML who have a susceptible IDH1 mutation. At the 63rd American Society of Hematology Annual Meeting in 2021, the data were presented to show that TIBSOVO® in combination with azacitidine significantly improved the event-free survival and overall survival in patients with treatment-naïve IDH1-mutated AML. We plan to hold regulatory discussions with the NMPA to bring this innovative therapy in combination with azacitidine to more Chinese patients as early as possible."
In China, TIBSOVO® was selected in the list of the third batch of Overseas New Drugs Urgently Needed in Clinical Settings by the Center for Drug Evaluation, NMPA in China, and granted fast-track designation. As a potent and highly selective first-in-class oral IDH1 inhibitor, TIBSOVO® was also recommended by the 2020 edition of the CSCO Guidelines for Diagnosis and Treatment of Hematological Malignancies due to its proven clinical advantages.
The approval of TIBSOVO® was based on the China registrational bridging study CS3010-101, which aimed to evaluate the pharmacokinetic (PK), pharmacodynamics (PD), safety, and clinical efficacy of orally administered TIBSOVO® in Chinese adult patients with R/R AML who have a susceptible IDH1 mutation. TIBSOVO® demonstrated robust clinical efficacy and a well-tolerated, manageable safety profile in the treatment of Chinese adults with R/R AML with a susceptible IDH1 mutation. Among 30 evaluable patients, the primary efficacy endpoint of complete remission plus complete remission with partial hematologic recovery (CR+CRh) rate was 36.7% (11/30) with all 11 patients achieving CR. The median duration of CR+CRh is not reached, and the estimated 12-month CR+CRh duration rate is 90.9%. The data were presented in a proffered paper presentation at the 2021 European Society for Medical Oncology (ESMO) Congress.
About TIBSOVO® (ivosidenib tablets)
TIBSOVO® is an oral targeted IDH1 inhibitor. The NMPA of China has approved the NDA of TIBSOVO® for the treatment of adult patients with relapsed/refractory acute myeloid leukemia who have a susceptible IDH1 mutation.
TIBSOVO® is currently approved in the U.S. as monotherapy for the treatment for the treatment of adults with IDH1-mutant relapsed or refractory acute myeloid leukemia (AML), and for adults with newly-diagnosed AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. In 2021, TIBSOVO® was the first and only targeted therapy approved for patients with previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1-mutation as detected by an FDA-approved test.
In addition, data from the global phase 3 study AGILE demonstrated that TIBSOVO® in combination with the chemotherapy azacitidine significantly improved event-free survival (HR=0.33) and overall survival (HR=0.44) compared to azacitidine plus placebo in patients with previously untreated IDH1-mutated acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy. The median overall survival (OS) of patients in the TIBSOVO® plus azacitidine arm was 24.0 months, compared with 7.9 months in the placebo plus azacitidine arm. There are very limited safe and effective treatment options for these newly diagnosed AML patients. The treatment of TIBSOVO® plus azacitidine has the potential to provide a new treatment option for treatment-naïve AML patients with IDH1 mutations who are not candidates for intensive chemotherapy.
The U.S. FDA has granted Breakthrough Therapy Designation for TIBSOVO® in combination with azacitidine for this supplemental indication and Breakthrough Therapy Designation for TIBSOVO® for the treatment of adult patients with relapsed or refractory myelodysplastic syndrome (MDS) with a susceptible IDH1 mutation.
Servier is the owner of TIBSOVO®'s rights and has granted an exclusive license to CStone to develop and commercialize the product in Mainland China, Taiwan, Hong Kong, Macau and Singapore.
About CStone
CStone Pharmaceuticals (HKEX: 2616) is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, CStone has received six drug approvals in Greater China, including four in Mainland China, one in Hong Kong, and one in Taiwan. CStone's vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide.
For more information about CStone, please visit: www.cstonepharma.com.
Forward-looking statement
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.
SOURCE CStone Pharmaceuticals
Eva Lee, head of Greater China equities at UBS Global Wealth Management, discusses China's property sector, the economy and her outlook for Chinese markets. She speaks on "Bloomberg Markets: China Open."
Aptevo Therapeutics Inc (NASDAQ: APVO) earned a million non-dilutive milestone payment related to 2021 sales of Ruxience, under the terms of its royalty purchase agreement with HealthCare Royalty Management LLC. Additionally, the Company is optimistic about the possibility of earning additional milestones totaling $22.5 million over the next two years. The Company also announced that its Phase 1b trial evaluating lead drug candidate APVO436 for acute myeloid leukemia (AML) continues to enroll ne
After a quiet session on Tuesday, economic data from Germany and Italy will need to impress as the markets await U.S inflation figures due out on Thursday.
The Alibaba Group-backed company, one of China's largest video platforms, came under public scrutiny last week after a user on microblogging platform Weibo said that the employee died after working long hours during the Spring Festival holiday, an allegation that went viral on social media. Local media reported Bilibili had in an internal letter on Monday said that his death was not caused by overtime. On Tuesday, the company released a public statement in which it published details of the case, stating that the employee had worked eight hours a day during the holiday.
As Novavax Inc. waits for regulators to approve its Covid-19 vaccine for adults in the U.S., the company has some good news concerning the younger population. The Gaithersburg biotech, which has been studying its vaccine in adolescents ages 12 through 17, said Thursday the candidate was effective in its phase 3 clinical trial. Simply put, Novavax’s vaccine candidate showed that it works in older kids by achieving that primary endpoint in the trial.
Who doesn’t like a bargain? In these days, with price inflation hitting hard, we all want to find the best price on every purchase – and that includes our stock purchases. Bargain-conscious investors can still find those fundamentally solid stocks that are trading low; this is the essence of successful stock investing. To make it easy, we’ve done some of the background research. We’ve located three stocks that are down 50% or more, and confirmed that these are Strong Buy stocks, that have gotten
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update New Pulmonary Programs Announced Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is developing medicines that cause gene silencing using RNA interference (RNAi), a specific means of inhibiting the expression of genes and stopping the production of a specific protein. The company has a deep and diverse pipeline
Molecular Partners AG (NASDAQ: MOLN) and its partner Novartis AG (NYSE: NVS), have requested FDA Emergency Use Authorization (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. This submission is based on the totality of the data from clinical and preclinical studies, including the results of the Phase 2 portion of the EMPATHY study, which enrolled 407 symptomatic COVID-19 patients. Related: Novartis To In-License COVID-19 Treatment From Molecular Partners, After Enc
Pfizer shares dropped sharply after the company’s 2022 sales guidance appeared to fall short of expectations. The guidance that Pfizer (ticker: PFE) presented, however, doesn’t take into account future sales of Pfizer’s Covid-19 vaccine and antiviral, but only sales already made. In its earnings release, Pfizer said it expected revenues of between $98 billion and $102 billion in 2022, including Covid vaccine sales of $32 billion and Covid antiviral sales of $22 billion.
Again and again, Hannah Catton told doctors something was wrong with her body. Again and again, she said, the doctors dismissed her concerns. They didn't listen in late 2018 when she told them about her frequent urinary tract infections. They didn't listen months later when she returned to tell them she was having irregular periods. And they didn't listen when she complained of bloating, constipation, diarrhea and extreme pain.Subscribe to The Post Most newsletter for the most important and inte
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
In 2021 investors looked to rapidly diversify their portfolios with biotech stocks as the development and deployment of the COVID-19 vaccine gained momentum around the world.
Conservative figures have launched an online furor this week, claiming that the government planned to spend $30 million on pipes for smoking crack cocaine. The heightened concern came months after the Department of Health and Human Services announced a federal grant for local programs that provide myriad "harm reduction" tools, or services that minimize the risks associated with drug use, including distributing drug paraphernalia such as clean needles. Republicans seized on "crack pipes," causin
Investing in businesses that will benefit from COVID-19 products, including vaccines, can be incredibly risky. Two such stocks that have enjoyed incredible success over the past two years are Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) — they've both soared more than 700%. Moderna's COVID-19 vaccine is currently fully approved for use in the U.S. in people who are at least 18 years of age.
Dr. Andre Campbell, UCSF professor of surgery and ICU Physician at Zuckerberg San Francisco General Hospital, joins Yahoo Finance Live to discuss COVID cases, hospitalizations, new variants, and Johnson & Johnson's temporary production pause for its vaccine.
Long after recovery from COVID-19, people face significantly higher risks for new heart problems, a large study has found. Researchers at the U.S. Department of Veterans Affairs compared rates of new cardiovascular problems in 153,760 individuals infected with the coronavirus before vaccines were available, 5.6 million people who did not catch the virus, and another 5.9 million people whose data was collected before the pandemic. An average of one year after their recovery from the acute phase of the infection, the COVID-19 survivors had a 63% higher risk for heart attack, a 69% higher risk for problematic irregular heart rhythm, a 52% higher risk of stroke, a 72% higher risk of heart failure, and a nearly three times higher risk of a potentially fatal blood clot in the lungs compared with the other two groups, according to a report published on Monday in Nature Medicine.
Surgeon General Dr. Joseph Ladapo faced his second hearing before Florida senators Tuesday.
COVID vaccine uptake in children has been slower than anticipated.
Counterfeit N95 and KN95 masks are flooding the market. Here's how to tell if a respirator is real or fake, and how to buy a NIOSH-approved mask.
Adams appears to have had some personal success with a vegan diet after a health scare, but can he replicate it among all New Yorkers? Eric Adams in New York City on 22 June 2021. Photograph: Anadolu Agency/Getty Images One morning in March 2016, before Eric Adams burst onto the national stage as the charismatic new mayor of New York City, he had a very rude awakening. The then Brooklyn borough president was startled to find that he could barely see the alarm clock that was sounding his morning


Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart